NYSE:MNK - Mallinckrodt Stock Price, Price Target & More

$13.7648 -0.28 (-1.99 %)
(As of 04/20/2018 12:00 PM ET)
Previous Close$14.04
Today's Range$13.74 - $14.0250
52-Week Range$13.32 - $49.12
Volume728,336 shs
Average Volume3.71 million shs
Market Capitalization$1.21 billion
P/E Ratio1.84
Dividend YieldN/A
Beta1.12

About Mallinckrodt (NYSE:MNK)

Mallinckrodt logoMallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MNK
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Debt-to-Equity Ratio0.98%
Current Ratio2.18%
Quick Ratio1.85%

Price-To-Earnings

Trailing P/E Ratio1.84
Forward P/E Ratio2.23
P/E Growth0.35

Sales & Book Value

Annual Sales$3.22 billion
Price / Sales0.37
Cash Flow$16.0056 per share
Price / Cash0.86
Book Value$68.65 per share
Price / Book0.20

Profitability

EPS (Most Recent Fiscal Year)$7.49
Net Income$2.13 billion
Net Margins66.25%
Return on Equity13.43%
Return on Assets4.95%

Miscellaneous

Employees3,900
Outstanding Shares86,350,000

How to Become a New Pot Stock Millionaire

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt's stock buyback program work?

Mallinckrodt declared that its board has authorized a stock buyback plan on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 18.5% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt (NYSE:MNK) released its quarterly earnings results on Tuesday, February, 27th. The company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.72 by $0.29. The business had revenue of $792.30 million for the quarter, compared to the consensus estimate of $769.91 million. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. Mallinckrodt's quarterly revenue was down 4.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.91 EPS. View Mallinckrodt's Earnings History.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Mallinckrodt.

What guidance has Mallinckrodt issued on next quarter's earnings?

Mallinckrodt updated its FY earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $6.00-6.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.14. The company issued revenue guidance of +3-6% to ~$.

What price target have analysts set for MNK?

18 Wall Street analysts have issued 12-month price targets for Mallinckrodt's shares. Their forecasts range from $15.00 to $67.00. On average, they anticipate Mallinckrodt's share price to reach $33.8889 in the next year. View Analyst Ratings for Mallinckrodt.

What are Wall Street analysts saying about Mallinckrodt stock?

Here are some recent quotes from research analysts about Mallinckrodt stock:
  • 1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) During the quarter, MNK’s cash flow from operations was ~$279MM, with free cash flow of ~ $244MM. 2) MNK repurchased 9.4MM shares in 4Q17, or ~10% of outstanding shares in the last quarter. 3) Net debt was ~$5.5B, and MNK drew on its revolver in preparation for the SCMP (Not Covered) transaction. Net debt leverage was 4.0x as of the end of the year. 4) Acthar sales in the quarter were $295MM (FactSet consensus was $288MM), a 9.3% YoY decrease, affected by the previously disclosed patient withdrawal issues. MNK has taken a number of steps to address the issue, including engagement with payers, prescribers and patients. MNK remains focused on returning Acthar to growth. 5) MNK seeks to reduce its annual SG&A spending by $100MM no later than the early-2020s, while continuing to increase R&D spending." (2/27/2018)
  • 2. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax.  As  a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018)

Who are some of Mallinckrodt's key competitors?

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:
  • Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)
  • Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)
  • Dr. Frank Scholz, Exec. VP of Global Operations & Pres of Specialty Generics (Age 49)
  • Mr. Hugh M. O'Neill, Exec. VP and Pres of Autoimmune & Rare Diseases (Age 55)
  • Dr. Gary M. Phillips, Exec. VP & Chief Strategy Officer (Age 52)

Has Mallinckrodt been receiving favorable news coverage?

News stories about MNK stock have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Mallinckrodt earned a news impact score of 0.17 on Accern's scale. They also gave media coverage about the company an impact score of 45.87 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $13.78.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $1.21 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt (MNK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  621 (Vote Outperform)
Underperform Votes:  367 (Vote Underperform)
Total Votes:  988
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mallinckrodt (NYSE:MNK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for Mallinckrodt in the last 12 months. Their average twelve-month price target is $33.8333, suggesting that the stock has a possible upside of 145.80%. The high price target for MNK is $67.00 and the low price target for MNK is $15.00. There are currently 1 sell rating, 12 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.222.332.372.78
Ratings Breakdown: 1 Sell Rating(s)
12 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.8333$38.50$44.6579$60.5278
Price Target Upside: 145.80% upside144.13% upside99.45% upside86.70% upside

Mallinckrodt (NYSE:MNK) Consensus Price Target History

Price Target History for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018MizuhoReiterated RatingHold$15.00LowView Rating Details
4/12/2018Stifel NicolausDowngradeBuy -> Hold$50.00HighView Rating Details
4/12/2018Wells FargoReiterated RatingHoldHighView Rating Details
4/11/2018SunTrust BanksInitiated CoverageHold$15.00HighView Rating Details
4/2/2018Cantor FitzgeraldSet Price TargetBuy$42.00HighView Rating Details
3/6/2018Canaccord GenuitySet Price TargetHold$20.00HighView Rating Details
2/27/2018OppenheimerReiterated RatingHoldHighView Rating Details
2/2/2018BarclaysDowngradeEqual Weight -> Underweight$23.00 -> $20.00MediumView Rating Details
1/2/2018Leerink SwannInitiated CoverageMkt Perform -> Market Perform$26.00MediumView Rating Details
1/1/2018Goldman SachsReiterated RatingHoldHighView Rating Details
11/26/2017UBSDowngradeBuy -> Neutral$70.00 -> $24.00MediumView Rating Details
11/8/2017Morgan StanleyLower Price TargetEqual Weight$40.00 -> $27.00N/AView Rating Details
11/8/2017BMO Capital MarketsLower Price TargetOutperform$38.00N/AView Rating Details
11/8/2017Jefferies GroupInitiated CoverageMarket Perform -> Buy$60.00 -> $30.00N/AView Rating Details
11/7/2017CitigroupDowngradeBuy -> Hold$44.00 -> $28.00N/AView Rating Details
11/7/2017Deutsche BankDowngradeBuy -> Hold$44.00 -> $28.00N/AView Rating Details
10/21/2017Piper JaffraySet Price TargetBuy$67.00N/AView Rating Details
8/9/2017Raymond JamesLower Price TargetOutperform$65.00 -> $58.00LowView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
1/25/2017JPMorgan ChaseSet Price TargetHold$78.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Mallinckrodt (NYSE:MNK) Earnings History and Estimates Chart

Earnings by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Earnings Estimates

2018 EPS Consensus Estimate: $6.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$1.08$1.55$1.22
Q2 20184$1.51$1.66$1.58
Q3 20184$1.58$2.07$1.78
Q4 20184$1.80$1.98$1.90

Mallinckrodt (NYSE MNK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$1.26N/AView Earnings Details
2/27/2018Q4 2017$1.72$2.01$769.91 million$792.30 millionViewListenView Earnings Details
11/7/2017Q3 2017$1.80$1.97$808.93 million$793.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017$1.73$1.85$829.56 million$824.50 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Mallinckrodt (NYSE:MNK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mallinckrodt (NYSE MNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%
Insider Trading History for Mallinckrodt (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE MNK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2017Dr Kneeland YoungbloodDirectorBuy4,560$21.94$100,046.4019,789View SEC Filing  
11/13/2017Joann A ReedDirectorBuy1,000$21.50$21,500.0015,554View SEC Filing  
11/13/2017Steven J. RomanoVPBuy2,000$21.96$43,920.00View SEC Filing  
11/10/2017Mark TrudeauCEOBuy5,000$22.28$111,400.00View SEC Filing  
11/9/2017David R CarlucciDirectorBuy10,000$21.83$218,300.0026,020View SEC Filing  
11/9/2017Michael-Bryant HicksGeneral CounselBuy7,900$20.80$164,320.00View SEC Filing  
8/30/2017Meredith B. FischerInsiderBuy1,280$39.63$50,726.40View SEC Filing  
6/9/2017Steven J. RomanoVPBuy1,000$39.88$39,880.00View SEC Filing  
6/8/2017Hugh M. O'neillVPBuy1,000$40.24$40,240.00View SEC Filing  
6/5/2017Coleman N Lannum IIIVPBuy500$39.33$19,665.0031,455View SEC Filing  
6/2/2017Coleman N Lannum IIIVPBuy1,350$42.89$57,901.5030,955View SEC Filing  
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.4715,623View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.0056,036View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00192,546View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.009,291View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.0020,556View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.0017,643View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.0017,940View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.0017,340View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.0011,266View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.002,549View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.007,728View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50167,526View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.009,986View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.0014,280View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.001,453View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.449,015View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00166,176View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.007,361View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00165,176View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mallinckrodt (NYSE MNK) News Headlines

Source:
DateHeadline
Mallinckrodts (MNK) Hold Rating Reiterated at MizuhoMallinckrodt's (MNK) Hold Rating Reiterated at Mizuho
www.americanbankingnews.com - April 20 at 11:53 AM
UBS Reiterates "Buy" Rating for Mallinckrodt (MNK)UBS Reiterates "Buy" Rating for Mallinckrodt (MNK)
www.americanbankingnews.com - April 20 at 11:19 AM
Mallinckrodt To Present At UBS Global Healthcare ConferenceMallinckrodt To Present At UBS Global Healthcare Conference
finance.yahoo.com - April 20 at 8:46 AM
Q4 2018 Earnings Forecast for Mallinckrodt (MNK) Issued By Leerink SwannQ4 2018 Earnings Forecast for Mallinckrodt (MNK) Issued By Leerink Swann
www.americanbankingnews.com - April 18 at 8:39 AM
Mallinckrodt (MNK) PT Set at $87.00 by Canaccord GenuityMallinckrodt (MNK) PT Set at $87.00 by Canaccord Genuity
www.americanbankingnews.com - April 17 at 10:21 PM
Are The Shorts Right About Mallinckrodt?Are The Shorts Right About Mallinckrodt?
seekingalpha.com - April 17 at 5:39 PM
U.S. drug agency proposes rules to rein in opioid manufacturingU.S. drug agency proposes rules to rein in opioid manufacturing
finance.yahoo.com - April 17 at 5:39 PM
Brokers Issue Forecasts for Mallinckrodts Q1 2018 Earnings (MNK)Brokers Issue Forecasts for Mallinckrodt's Q1 2018 Earnings (MNK)
www.americanbankingnews.com - April 17 at 6:51 AM
BRIEF-Mallinckrodt Announces $300 Million Debt RepaymentBRIEF-Mallinckrodt Announces $300 Million Debt Repayment
www.reuters.com - April 16 at 5:06 PM
Whistleblower Claims Mallinckrodt Is Scheming To Spike Acthar SalesWhistleblower Claims Mallinckrodt Is Scheming To Spike Acthar Sales
seekingalpha.com - April 16 at 5:06 PM
Mallinckrodt plc Announces $300 Million Debt RepaymentMallinckrodt plc Announces $300 Million Debt Repayment
finance.yahoo.com - April 16 at 5:06 PM
Q1 2018 Earnings Estimate for Mallinckrodt (MNK) Issued By SunTrust BanksQ1 2018 Earnings Estimate for Mallinckrodt (MNK) Issued By SunTrust Banks
www.americanbankingnews.com - April 16 at 1:19 AM
Zacks Investment Research Upgrades Mallinckrodt (MNK) to HoldZacks Investment Research Upgrades Mallinckrodt (MNK) to Hold
www.americanbankingnews.com - April 15 at 6:44 PM
$570.67 Million in Sales Expected for Mallinckrodt (MNK) This Quarter$570.67 Million in Sales Expected for Mallinckrodt (MNK) This Quarter
www.americanbankingnews.com - April 14 at 4:20 AM
Mallinckrodts (MNK) Buy Rating Reiterated at Jefferies GroupMallinckrodt's (MNK) Buy Rating Reiterated at Jefferies Group
www.americanbankingnews.com - April 13 at 11:42 PM
The Mallinckrodt/Acthar Mess Has Only Just Begun And Could Be Bigger Than Anyone Could Imagine (Podcast)The Mallinckrodt/Acthar Mess Has Only Just Begun And Could Be Bigger Than Anyone Could Imagine (Podcast)
seekingalpha.com - April 13 at 5:14 PM
Mallinckrodt (MNK) PT Set at $85.00 by Piper JaffrayMallinckrodt (MNK) PT Set at $85.00 by Piper Jaffray
www.americanbankingnews.com - April 13 at 12:58 AM
Mallinckrodt (MNK) Stock Rating Lowered by BidaskClubMallinckrodt (MNK) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 12 at 6:14 PM
Mallinckrodt shares slide on whistleblower lawsuit involving its best-selling drugMallinckrodt shares slide on whistleblower lawsuit involving its best-selling drug
www.cnbc.com - April 12 at 2:58 PM
Mallinckrodt (MNK) Receives Hold Rating from Stifel NicolausMallinckrodt (MNK) Receives Hold Rating from Stifel Nicolaus
www.americanbankingnews.com - April 12 at 2:19 PM
Mallinckrodt (MNK) Rating Reiterated by Wells FargoMallinckrodt (MNK) Rating Reiterated by Wells Fargo
www.americanbankingnews.com - April 12 at 1:16 PM
Mallinckrodt (MNK) Given a $87.00 Price Target by Canaccord Genuity AnalystsMallinckrodt (MNK) Given a $87.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 12 at 11:27 AM
 Brokerages Expect Mallinckrodt (MNK) Will Announce Earnings of $1.14 Per Share Brokerages Expect Mallinckrodt (MNK) Will Announce Earnings of $1.14 Per Share
www.americanbankingnews.com - April 12 at 8:47 AM
UBS Analysts Give Mallinckrodt (MNK) a $70.00 Price TargetUBS Analysts Give Mallinckrodt (MNK) a $70.00 Price Target
www.americanbankingnews.com - April 11 at 11:52 PM
Deutsche Bank Analysts Give Mallinckrodt (MNK) a $56.00 Price TargetDeutsche Bank Analysts Give Mallinckrodt (MNK) a $56.00 Price Target
www.americanbankingnews.com - April 11 at 7:18 PM
Mallinckrodt (MNK) Coverage Initiated by Analysts at SunTrust BanksMallinckrodt (MNK) Coverage Initiated by Analysts at SunTrust Banks
www.americanbankingnews.com - April 11 at 5:35 PM
Theres other s--- in the vial: Bombshell lawsuit claims no one knows exactly whats in a drug thats cost the ...'There's other s--- in the vial': Bombshell lawsuit claims no one knows exactly what's in a drug that's cost the ...
www.businessinsider.com - April 11 at 5:11 PM
Mallinckrodt To Present At Deutsche Banks 43rd Annual Healthcare ConferenceMallinckrodt To Present At Deutsche Bank's 43rd Annual Healthcare Conference
finance.yahoo.com - April 9 at 8:46 AM
ValuEngine Upgrades Mallinckrodt (MNK) to "Buy"ValuEngine Upgrades Mallinckrodt (MNK) to "Buy"
www.americanbankingnews.com - April 8 at 11:48 AM
Mallinckrodt (MNK) Expected to Earn FY2018 Earnings of $6.03 Per ShareMallinckrodt (MNK) Expected to Earn FY2018 Earnings of $6.03 Per Share
www.americanbankingnews.com - April 6 at 6:54 AM
Form 4 Mallinckrodt plc For: Apr 02 Filed by: ONeill Hugh M.Form 4 Mallinckrodt plc For: Apr 02 Filed by: O'Neill Hugh M.
www.streetinsider.com - April 5 at 10:39 AM
Form 4 Mallinckrodt plc For: Apr 02 Filed by: LLOYD RONALD K.Form 4 Mallinckrodt plc For: Apr 02 Filed by: LLOYD RONALD K.
www.streetinsider.com - April 5 at 10:39 AM
Mallinckrodt (MNK) Given Average Recommendation of "Hold" by AnalystsMallinckrodt (MNK) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 5 at 5:34 AM
BRIEF-Mallinckrodt Names Paul Carter, Anne Whitaker To Its Board Of DirectorsBRIEF-Mallinckrodt Names Paul Carter, Anne Whitaker To Its Board Of Directors
www.reuters.com - April 4 at 8:41 AM
Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018
finance.yahoo.com - April 4 at 8:41 AM
Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of DirectorsMallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors
finance.yahoo.com - April 4 at 8:41 AM
Mallinckrodt (MNK) Downgraded by ValuEngine to "Sell"Mallinckrodt (MNK) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 3 at 12:10 PM
Mallinckrodt (MNK) Given a $42.00 Price Target by Cantor Fitzgerald AnalystsMallinckrodt (MNK) Given a $42.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 3 at 10:37 AM
Mallinckrodts (MNK) Buy Rating Reiterated at Cantor FitzgeraldMallinckrodt's (MNK) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 1 at 11:24 PM
Mallinckrodt (MNK) Raised to Hold at Zacks Investment ResearchMallinckrodt (MNK) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 1 at 7:35 PM
Mallinckrodt (MNK) Stock Rating Lowered by Wells FargoMallinckrodt (MNK) Stock Rating Lowered by Wells Fargo
www.americanbankingnews.com - April 1 at 11:24 AM
Mallinckrodt (MNK) Receives New Coverage from Analysts at Jefferies GroupMallinckrodt (MNK) Receives New Coverage from Analysts at Jefferies Group
www.americanbankingnews.com - April 1 at 11:24 AM
Barclays Downgrades Mallinckrodt (MNK) to Equal WeightBarclays Downgrades Mallinckrodt (MNK) to Equal Weight
www.americanbankingnews.com - April 1 at 11:23 AM
Goldman Sachs Downgrades Mallinckrodt (MNK) to NeutralGoldman Sachs Downgrades Mallinckrodt (MNK) to Neutral
www.americanbankingnews.com - April 1 at 10:48 AM
BMO Capital Markets Trims Mallinckrodt (MNK) Target Price to $38.00BMO Capital Markets Trims Mallinckrodt (MNK) Target Price to $38.00
www.americanbankingnews.com - April 1 at 10:48 AM
Mallinckrodt (MNK) PT Lowered to $50.00Mallinckrodt (MNK) PT Lowered to $50.00
www.americanbankingnews.com - April 1 at 9:47 AM
Mallinckrodt (MNK) Price Target Cut to $27.00Mallinckrodt (MNK) Price Target Cut to $27.00
www.americanbankingnews.com - April 1 at 9:41 AM
President Trump Considers Suing Opioid ManufacturersPresident Trump Considers Suing Opioid Manufacturers
seekingalpha.com - April 1 at 8:39 AM
Mallinckrodt (MNK) Price Target Cut to $24.00Mallinckrodt (MNK) Price Target Cut to $24.00
www.americanbankingnews.com - April 1 at 12:40 AM
Mallinckrodts (MNK) "Hold" Rating Reiterated at Goldman SachsMallinckrodt's (MNK) "Hold" Rating Reiterated at Goldman Sachs
www.americanbankingnews.com - March 31 at 2:06 PM

SEC Filings

Mallinckrodt (NYSE:MNK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mallinckrodt (NYSE:MNK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mallinckrodt (NYSE MNK) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.